CREATV BIO STUDIES PRESENTED AT AACR ANNUAL MEETING SHOWING IMPORTANCE OF MONITORING PD-L1, MITOTIC CTCs and CAMLs IN BLOOD

On May 20, 2026 Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, reported five posters in conjunction with several research collaborators at the 2026 AACR (Free AACR Whitepaper) Annual Meeting, held in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Mitosis in circulating tumor cells correlates with highly aggressive disease in metastatic breast cancer
Abstract: 1065

Key Finding: Circulating tumor cells (CTCs) undergoing mitosis is indicative of highly aggressive disease with poor survival rates.

2. Monitoring PD-L1 in tumor macrophage fusion cells in blood correlates to PD-L1 checkpoint inhibitor responses in metastatic breast cancer
Abstract: 1025

Key Finding: Monitoring PD-L1 in tumor macrophage fusion cells (TMFCs) serves as a real-time blood biomarker that predicts Immune Checkpoint Inhibitor (ICI) responses in metastatic breast cancer.

3. Combining circulating tumor cells and cancer associated macrophage-like cells enhances risk stratification models in pan-cancer metastatic disease
Abstract: 1068

Key Finding: Cancer associated macrophage-like cells (CAMLs) are a subtype of TMFCs. Simultaneous quantification of both CTCs and CAMLs allows for more accurate patient risk stratification.

4. Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC
Abstract: 1033

Key Finding: Monitoring PD-L1 expression on CTCs and CAMLs identifies PD-L1 upregulation after treatment with leronlimab.

5. Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
Abstract: 6466

Key Finding: Monitoring CTCs, CAMLs and ctDNA show promise as early assessments for clinical response when treated with leronlimab.

Creatv’s LifeTracDx blood test utilized CellSieve microfilters to isolate, collect and measure both CTCs and CAMLs (number and size) in each of the clinical studies above.

(Press release, Creatv Bio, MAY 20, 2026, View Source [SID1234665902])